AstraZeneca Plc and Bristol Myers Squibb reportedly engaged in preliminary discussions regarding a potential merger that could value the combined entity at nearly $400 billion. This would create one of the world's largest pharmaceutical companies. While details remain scarce, and it's unclear if talks are ongoing, the news led to a drop of up to 7% in AstraZeneca's shares, while Bristol Myers Squibb's shares rose 6% in premarket trading.
Analysts expressed puzzlement over the strategic rationale for such a deal, especially for AstraZeneca, which has seen strong growth and a robust drug pipeline under CEO Pascal Soriot, targeting $80 billion in sales by 2030. Jefferies analysts noted that AstraZeneca does not appear to need "financial engineering." One potential reason for the deal could be AstraZeneca's desire to further penetrate the crucial U.S. market, given that 42% of its first-half 2026 sales were from the U.S., while Bristol Myers Squibb sourced 69% of its recent revenues from the U.S.
The proposed megadeal faces significant regulatory scrutiny, particularly from U.S. antitrust authorities under President Donald Trump's administration, which focuses on domestic investments and expanding U.S. manufacturing. Lawyers like Andre Barlow of DBM Law Group anticipate that the U.S. Federal Trade Commission (FTC) would examine overlaps in drugs and late-stage pipelines, potentially requiring meaningful divestitures. Both companies have strong oncology portfolios, with AstraZeneca excelling in solid tumors and Bristol Myers Squibb in blood cancers, which could attract antitrust concerns. Bristol Myers Squibb is also facing patent expirations for key drugs like Eliquis and Opdivo by 2028.
As of Monday trading, AstraZeneca had a market capitalization of $264 billion, while Bristol Myers Squibb's was roughly $133 billion. In 2025, AstraZeneca's cancer treatments accounted for about $25 billion in sales, nearly half its total, with cardiovascular, renal, and metabolism treatments contributing around $12 billion. Bristol Myers Squibb's oncology drugs made up over 40% of its sales in the first half of 2026. The companies have overlapping interests in oncology, cardiovascular disease, and immunology, but their pipelines are largely complementary.
